He has chaired committees for the VA, FDA (Blood Products Advisory Committee) and Chair NIH-CSR (AIDS Immunology Pathogenesis Study Section). Douglas has been President, Society for Leukocyte Biology. He is testing NK1R antagonists as therapy for HIV patients.ĭr. He detected SP-preferring receptor, neurokinin-1 (NK1R), in monocytes, and that SP antagonists inhibit HIV. He developed methods for isolation-differentiation of blood monocytes into macrophages and showed the role of macrophages in HIV. Douglas discovered pokeweed mitogen as a lymphocyte stimulator and developed tests to diagnose immune deficiency diseases. Ongoing studies have demonstrated associations between substance P, impaired natural killer cell activity and depression in HIV-infected individuals.Įarly in his career, Dr. He has recently instigated studies involving psychosocial and psychiatric interactions with the immune and nervous systems. Douglas has extensive experience in cellular and humoral immunologic studies, including studies of AIDS infection and of primary immunodeficiencies. His laboratory is actively involved in research in cellular immunology and its relationship to the immunopathogenesis of HIV. He has also demonstrated up-regulation of substance P by HIV. He discovered the truncated from of NK1-R in human cells and demonstrated that SP antagonists block HIV through CCR5 and he has applied as NK1R antagonists novel HIV therapy. Douglas' ongoing research program involves molecular and cellular immunologic studies of substance P and its receptor, Neurokinin-1 in monocyte-macrophages. The Douglas laboratory does basic, translational, and clinical research.ĭr. These networks are state-of-the-art therapeutic trials for adult and pediatric HIV/AIDS throughout the world. He is also the PI for the Adolescent Trial Network (NICHD). Douglas’ laboratory is the central immunology laboratory for the IMPAACT Network, and a specialty immunology laboratory. He is the Principal Investigator for the Philadelphia International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Unit, which includes a Clinical Research Site at CHOP, Clinical Research Site at the Adult Unit at the Hospital of the University of Pennsylvania, and two Satellites (Hospital of the University of Pennsylvania and Pennsylvania Hospital)(NIAID). He and his group investigate the interaction between neuropeptides, monocyte-macrophages and HIV. He is the PI for a U01, Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 Antagonists (NIMH) (through 2014), which encompasses three Projects (including a clinical trial) and two Cores (including Pharmacology and Biostatistics). His laboratory is funded by a longstanding R01,Tachykinins Mononuclear Phagocytes and HIV-1 Infection. Douglas has been investigating cellular immune mechanisms and monocyte-macrophages. Key words: Substance P, Neurokinin-1 Receptorĭr. Interaction between immune system and brain and HIV, Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy, HIV and NK1-R immune activation and suppression in psychiatric disease. Schwartz said, adding that he felt embarrassed, humiliated and deeply remorseful.Description of Research Expertise Research Interests “God, I wish I did that, and I didn’t do it,” Mr. He repeatedly tried to explain why he did not conduct further research into the cases that ChatGPT had provided to him. Schwartz squeezed his eyes shut and rubbed his forehead with his left hand. Schwartz and his partner, Peter LoDuca, whose name was on the brief.Īt times during the hearing, Mr. Kevin Castel, said he would now consider whether to impose sanctions on Mr. Schwartz was grilled by a judge in a hearing ordered after the disclosure that the lawyer had created a legal brief for a case in Federal District Court that was filled with fake judicial opinions and legal citations, all generated by ChatGPT. Schwartz sat slumped, his shoulders drooping and his head rising barely above the back of his chair.įor nearly two hours Thursday, Mr. Schwartz, appeared nervously upbeat, grinning while talking with his legal team. As the court hearing in Manhattan began, the lawyer, Steven A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |